Berenguer, JuanRivero, AntonioJarrin Vera, InmaculadaNúñez, María JVivancos, María JCrespo, ManelTéllez, María JesúsDomingo, PereIribarren, José AntonioArtero, ArturoMárquez, ManuelSantos, IgnacioMoreno, JavierMontero, MartaGonzález-García, JuanGeSIDA 8514 Study Group2022-04-072022-04-072016-03Open Forum Infect Dis. 2016;3(2):ofw059.2328-8957http://hdl.handle.net/20.500.12105/13958Background: The purpose of this study was to assess the prevalence of anti-hepatitis C virus (HCV) antibodies (Abs) and active HCV infection in human immunodeficiency virus (HIV)-infected (HIV+) patients in Spain in 2015. This was a cross-sectional study. Methods: The study was performed in 41 centers in 2015. Sample size was estimated for an accuracy of 2%, the number of patients from each hospital was determined by proportional allocation, and patients were selected using simple random sampling. Results: The reference population was 35 791 patients, and the sample size was 1867 patients. Hepatitis C virus serostatus was known in 1843 patients (98.7%). Hepatitis C virus-Abs were detected in 695 patients (37.7%), in whom the main route of HIV acquisition was injection drug use (75.4%). Of these 695 patients, 402 had HCV RNA, 170 had had a sustained viral response (SVR) after anti-HCV therapy, and 102 cleared HCV spontaneously. Hepatitis C virus-ribonucleic acid results were unknown in 21 cases. Genotype distribution (known in 367 patients) was 1a in 143 patients (39.0%), 4 in 90 (24.5%) patients, 1b in 69 (18.8%) patients, 3 in 57 (15.5%) patients, 2 in 5 (1.4%) patients, and mixed in 3 (0.8%) patients. Liver cirrhosis was present in 93 patients (23.1%) with active HCV infection and in 39 (22.9%) patients with SVR after anti-HCV therapy. Conclusions: The prevalence of HCV-Abs and active HCV infection in HIV+ patients in Spain is 37.7% and 22.1%, respectively; these figures are significantly lower than those recorded in 2002 and 2009. The predominant genotypes in patients with active HCV infection were 1a and 4. A high percentage of patients had cirrhosis. Cirrhosis is also common in patients with SVR after anti-HCV therapy.engVoRhttps://creativecommons.org/licenses/by-nc-nd/4.0/HIV infections/epidemiologySpain/epidemiologyCoinfection/epidemiologyHepatitis C/drug therapy/epidemiologyAttribution-NonCommercial-NoDerivs 4.0 International2718658432ofw05910.1093/ofid/ofw059Open Forum Infectious Diseasesopen access